CGH
BLFS icon

Crossmark Global Holdings’s BioLife Solutions BLFS Stock Holding History

Crossmark Global Holdings’s Portfolio BLFS Stock Details BLFS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-15,800
Closed -$669K – 1385
2021
Q3 		$669K Buy
+15,800
New +$761K 0.02% 776

Other funds holding BLFS

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
GCM
Geneva Capital Management Milwaukee, Wisconsin $4.71B AUM 6.32% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Crossmark Global Holdings's BLFS Position: Q4 2021 in Review

Crossmark Global Holdings sold out of BioLife Solutions (BLFS) in Q4 2021, closing a stake of 15,800 shares — an estimated $669K sold.

Crossmark Global Holdings first reported a position in BLFS in Q3 2021 and held it in 1 quarter. The position peaked at $669K in Q3 2021. 169 funds tracked by Wall St. Rank hold BLFS as of Q4 2021.

  • Crossmark Global Holdings reported no remaining BioLife Solutions position as of Q4 2021 after selling out during the quarter.
  • Crossmark Global Holdings sold 15,800 BioLife Solutions shares in Q4 2021, an estimated $669K.
  • Crossmark Global Holdings first reported a position in BioLife Solutions in Q3 2021 and held it in 1 quarter.
  • Crossmark Global Holdings's BioLife Solutions position peaked at $669K in Q3 2021.
  • 169 funds tracked by Wall St. Rank held BioLife Solutions as of Q4 2021.

Based on Crossmark Global Holdings's 13F filing for Q4 2021, filed 10 Jan 2022.